

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody

RRID:AB_2892127

Type: Antibody

Proper Citation

Abcam Cat# ab275759, RRID:AB_2892127

Antibody Information

URL: http://antibodyregistry.org/AB_2892127

Proper Citation: Abcam Cat# ab275759, RRID:AB_2892127

Target Antigen: Spike Glycoprotein S1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: IHC-P, ICC, ELISA, WB

Antibody Name: Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody

Description: This polyclonal targets Spike Glycoprotein S1

Target Organism: sarscov2

Antibody ID: AB_2892127

Vendor: Abcam

Catalog Number: ab275759

Record Creation Time: 20231110T031632+0000

Record Last Update: 20260901T025009+0000

Ratings and Alerts

No rating or validation information has been found for Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody.

No alerts have been found for Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Papp H, et al. (2024) The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19. British journal of pharmacology, 181(23), 4782.

Cooper A, et al. (2022) A genetically engineered, stem-cell-derived cellular vaccine. Cell reports. Medicine, 3(12), 100843.